Site search
2923 results for '' found
A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cance
A First-in-Human Study of Mutant-selective PI3Ka Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cance
/
A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke w
A phase 2b, multinational, randomized, double-blind study to investigate the efficacy and safety of redasemtide (S-005151) compared with placebo in adult participants with acute ischemic stroke w
/
Evaluation of the RibFix™ Advantage Rib Fixation System for Surgical Repair of Rib Fractures (Trial Not Registered)
Evaluation of the RibFix™ Advantage Rib Fixation System for Surgical Repair of Rib Fractures (Trial Not Registered)
/
Unravelling the reversibility of pulmonary vascular disease in HFpEF, aortic stenosis and CTEPH after intervention: the REVERS-PVD study (Trial Not Registered)
Unravelling the reversibility of pulmonary vascular disease in HFpEF, aortic stenosis and CTEPH after intervention: the REVERS-PVD study (Trial Not Registered)
/
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-Week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects with Mild-to-moderate Alzheimer’s
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-Week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects with Mild-to-moderate Alzheimer’s
/
RESpiratory pathogen Point-Of-Care Testing in Emergency Departments (ACTRN12625000123448)
RESpiratory pathogen Point-Of-Care Testing in Emergency Departments (ACTRN12625000123448)
/
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomon
A Double-Blind, Active-Controlled, Multiple-Ascending Dose, Phase 1b Study of Aerosolized RSP-1502 Delivered Via the PARI LC Plus® Nebulizer in Subjects with Cystic Fibrosis and Chronic Pseudomon
/
A multicenter, randomized, double-blind, chronic-dosing, parallel-group, placebo-controlled phase 3 study to evaluate the efficacy and safety of bendralizumab 100mg in patietns with moderate to v
A multicenter, randomized, double-blind, chronic-dosing, parallel-group, placebo-controlled phase 3 study to evaluate the efficacy and safety of bendralizumab 100mg in patietns with moderate to v
/
Randomized,Embedded,Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) (NCT02735707)
Randomized,Embedded,Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) (NCT02735707)
/
A prospective, double-blinded, randomised study comparing 16g automated full-core and side-notch biopsy needles for percutaneous renal biopsies in renal transplant patients (Trial Not Registered)
A prospective, double-blinded, randomised study comparing 16g automated full-core and side-notch biopsy needles for percutaneous renal biopsies in renal transplant patients (Trial Not Registered)
/